Abstract:Introduction: Histone deacetylases (HDACs)are crucial in regulating gene expression, DNA synthesis, and metabolic processes, including cancer, in various cellular environments. The unique structural and functional attributes of class IIb HDAC6 position it as a key player in influencing protein stability and chromatin dynamics. While its role in cancer progression and immunomodulation is well-recognized, the in-depth mechanisms following HDAC6 inactivation, particularly its influence on chromatin remodeling and gene regulation, are not thoroughly understood. This knowledge gap represents a critical area of investigation, given the potential of HDAC6 as a therapeutic target in oncology. This study aims to elucidate HDAC6 inactivation-dependent epigenetic effects of, exploring the possibility to exploit these latter for therapeutic purposes in cancer. This aim includes an examination of the stabilization of the lysine acetyltransferase P300 and its implications for chromatin structure and function. Methods & Results: In this study, ITF3756 and CRISPR/Cas9 were employed to inactivate HDAC6 across a variety of cancer cell lines (Jurkat, MDA 231, HCC1806, 4T1, and B16F10 melanoma). ATAC-seq and H3K27Ac ChIP-seq were used to investigate changes in chromatin accessibility, revealing significant alterations, particularly in introns and distal intergenic regions. Gene Ontology (GO) analysis further supported this alteration in the chromatin landscape, which indicated a differential expression of genes involved in critical cellular processes like cell proliferation, adhesion, migration, and apoptosis. A notable outcome of this study was the stabilization of P300 following ITF3756 treatment, an effect that was paralleled by changes in the expression of critical genes, including AKT1, ITGB3, GAS6, SOX9, NF1, TGFB2, and CASP7. These genes are integral to cellular survival mechanisms, and their modulation emphasizes the role of HDAC6 in cancer cell physiology. Conclusions: This research shows that the chemical or genetic inactivation of HDAC6 impacts cancer cell proliferation and chromatin architecture, underscoring the potential of HDAC6 as a target in cancer therapeutics.. A critical finding of this study is the stabilization of P300, which offers new perspectives on HDAC6's functionality and its role as an epigenetic modifier in cancer cells. This study contributes to the field by suggesting therapeutic strategies focusing on HDAC/HAT pharmacological targeting, thereby advancing our understanding of the role of HDAC6 in regulating cancer cell behavior and epigenetic landscape. Citation Format: Michela Gottardi Zamperla, Barbara Illi, Veronica Barbi, Chiara Cencioni, Stella Gagliardi, Maria Garofalo, Gabriele Antonio Zingale, Irene Pandino, Diego Sbardella, Lina Cipolla, Simone Sabbioneda, Antonella Farsetti, Chiara Ripamonti, Gianluca Fossati, Christian Steinkühler, Sandra Atlante, Carlo Gaetano. HDAC6 inhibition reshapes the epigenome of cancer via P300 stabilization [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 4582.

HDAC6 inhibitor ACY-1215 enhances STAT1 acetylation to block PD-L1 for colorectal cancer immunotherapy

Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells

HDAC5 modulates PD-L1 expression and cancer immunity via p65 deacetylation in pancreatic cancer

HDAC Inhibition Potentiates Anti-Tumor Activity of Macrophages and Enhances Anti-Pd-l1-mediated Tumor Suppression

HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma

HDAC6 selective inhibition of melanoma patient T-cells augments anti-tumor characteristics

HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade

Optimized dose selective HDAC inhibitor tucidinostat overcomes anti-PD-L1 antibody resistance in experimental solid tumors

Abstract 1359: Selective HDAC6 inhibition by GB-1101 revokes tumor immune privilege and synergizes with immune checkpoint therapies to induce tumor regressions

Immune modulation underpins the anti-cancer activity of HDAC inhibitors

HDAC6 promotes cell proliferation and confers resistance to gefitinib in lung adenocarcinoma.

Histone deacetylase inhibitors prevent activation-induced cell death and promote anti-tumor immunity

HDAC3 Inhibition Upregulates PD-L1 Expression in B-Cell Lymphomas and Augments the Efficacy of Anti-PD-L1 Therapy

HDAC Inhibitor, CG-745, Enhances the Anti-Cancer Effect of Anti-PD-1 Immune Checkpoint Inhibitor by Modulation of the Immune Microenvironment

ACY-241, an HDAC6 inhibitor, overcomes erlotinib resistance in human pancreatic cancer cells by inducing autophagy

Abstract 4582: HDAC6 inhibition reshapes the epigenome of cancer via P300 stabilization

Abstract 4583: Development of selective HDAC6 inhibitors to improve cancer immunotherapy

HDAC-targeting epigenetic modulators for cancer immunotherapy

Inhibiting stromal Class I HDACs curbs pancreatic cancer progression

Targeting HDAC6 improves anti-CD47 immunotherapy

Therapeutic potential of tucidinostat, a subtype-selective HDAC inhibitor, in cancer treatment